New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol
Mario Cazzola,1 Andrea Segreti,1 Maria Gabriella Matera2 1Department of System Medicine, University of Rome 'Tor Vergata', Rome, Italy; 2Department of Experimental Medicine, Second University, Naples, Italy Abstract: An increasing body of evidence suggests that the long-acting muscar...
Saved in:
Main Authors: | Cazzola M (Author), Segreti A (Author), Matera MG (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2013-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD
by: E. G. Kosolapov, et al.
Published: (2017) -
Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review
by: Spyratos D, et al.
Published: (2015) -
In Vitro Analysis of Aerodynamic Properties and Co-Deposition of a Fixed-Dose Combination of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate
by: Kittipong Maneechotesuwan, et al.
Published: (2024) -
Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation
by: Hamouda M, et al.
Published: (2023) -
Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
by: Matera MG, et al.
Published: (2015)